Illustration depicting multiple myeloma cells in the bone marrow, with elements representing hope and treatment advancements.

Early Myeloma Relapse: New Research Reveals Key Predictors and Hope for the Future

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 5 min read.

"Groundbreaking study identifies critical factors influencing early relapse in multiple myeloma and highlights promising advancements in treatment."


Multiple myeloma, a cancer of the plasma cells in bone marrow, presents significant challenges for patients and healthcare providers. While advancements in treatment have improved survival rates, early relapse remains a major concern. Understanding the factors that contribute to early relapse is crucial for developing targeted therapies and improving patient outcomes.

A recent study published in the journal Biology of Blood and Marrow Transplantation sheds light on the predictors of early relapse in multiple myeloma. The research, led by experts in the field, analyzed data from a large cohort of patients who underwent autologous hematopoietic cell transplantation (AHCT). The findings offer valuable insights into the disease and its progression.

This article delves into the key findings of the study, discussing the impact of the Revised International Staging System (R-ISS), the role of maintenance therapy, and the implications for patients. We will explore how this research can guide future treatment strategies and offer hope for improved outcomes in the fight against multiple myeloma.

AI Search Multiple angles on this topic

The Burden of Early Relapse

Despite major advances in multiple myeloma treatment over the past two decades, outcomes remain heterogenous, with some patients being primary refractory and others being long-term non-progressors. There is an unmet need to identify patients at risk for early relapse or progression upfront to tailor new treatment strategies and improve outcomes. An analysis of 10,843 patients with newly-diagnosed multiple myeloma treated in 16 international clinical trials from 2005 to 2016 sought to identify such patients. Multiple myeloma remains the second most common hematological malignancy, characterized by bone marrow infiltration by plasma cells producing monoclonal immunoglobulin.

Current Treatment Landscape

The treatment of multiple myeloma has evolved significantly, with options now including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and cellular therapies. Initial therapy is rarely curative, and almost all patients with multiple myeloma ultimately progress. While the rapidly evolving treatment landscape offers many options, choosing the most appropriate therapy remains challenging for many oncologists. This complexity underscores the need for clearer guidance and risk-stratified approaches to patient care.

Understanding Myeloma Evolution

Research has developed a two-step model for multiple myeloma development by reconstructing the timeline of mutational signature activity. The treatment landscape has undergone a profound transformation over the past two decades, driven by deeper insights into disease biology and refined patient stratification. The prognosis of multiple myeloma has considerably improved due to the introduction of novel agents in the upfront setting. However, the great majority of patients ultimately relapse, and choosing a salvage treatment at first relapse remains challenging.

Unraveling the Predictors of Early Relapse: The Role of the R-ISS and Other Factors

Illustration depicting multiple myeloma cells in the bone marrow, with elements representing hope and treatment advancements.

The study examined the Revised International Staging System (R-ISS) and its ability to predict early relapse, defined as relapse within 24 months of AHCT. The R-ISS combines the International Staging System (ISS) with genetic markers and lactate dehydrogenase levels to assess the risk of disease progression. The research revealed that patients with higher R-ISS stages (II and III) at diagnosis had a significantly increased risk of early relapse compared to those with stage I disease.

Beyond the R-ISS, the study identified other factors associated with an increased risk of early relapse. These included a higher HCT-CI (Hematopoietic Cell Transplantation-Comorbidity Index) score, indicating the presence of comorbidities, and the use of multiple lines of induction chemotherapy prior to AHCT. These findings underscore the complex nature of multiple myeloma and the importance of considering multiple factors when assessing prognosis.

  • R-ISS Stage: Patients with higher R-ISS stages (II and III) at diagnosis showed a higher risk of early relapse.
  • HCT-CI Score: A higher HCT-CI score, indicating more comorbidities, was associated with an increased risk.
  • Chemotherapy Lines: The use of multiple lines of induction chemotherapy before AHCT was linked to a higher risk.
AI Search Multiple angles on this topic

Advances in Detection and Management

Recent research has focused on improving the detection of early relapse in multiple myeloma patients. While the quality and length of life for myeloma patients have significantly increased, the disease remains hard to treat and almost all patients relapse. New evidence from the 2026 ASCO and EHA Congresses has provided insights into navigating early relapse in multiple myeloma. Ongoing studies continue to explore new therapeutic combinations and approaches to improve patient outcomes.

Challenges in Treatment Resistance

Despite therapeutic advances, multiple myeloma remains largely incurable, with many patients facing treatment resistance. The heterogeneity of the disease means that responses to therapy vary significantly among patients. Some patients experience primary refractory disease, while others achieve long-term remission. This variability highlights the limitations of current treatment approaches and the need for more personalized strategies.

Evaluating Treatment Options at Relapse

Although treatments have greatly improved outcomes in patients with newly diagnosed multiple myeloma, most patients will relapse after initial therapy and require subsequent treatment. With the wide variety of available treatment regimens and the need to tailor treatment based on disease- and patient-centric factors, choosing wisely at first relapse is critical. Treatments incorporating autologous transplantation, proteasome inhibitors, and immunomodulatory drugs induce deep and durable remissions in most patients, resulting in prolonged survival. However, patients who suffer early relapse within 2 years of treatment initiation or become refractory to these agents still have a dismal prognosis.

The research also evaluated the impact of maintenance therapy on post-relapse survival. While maintenance therapy is often used to prevent relapse, the study found that it did not significantly affect survival outcomes in the early relapse group. This suggests that the underlying biology of the disease plays a more significant role in determining outcomes for patients who experience early relapse.

Looking Ahead: Hope for Improved Outcomes

The research provides valuable insights into the predictors of early relapse in multiple myeloma and highlights the need for personalized treatment strategies. While early relapse remains a significant challenge, ongoing research into novel therapies and targeted approaches offers hope for improved outcomes. By understanding the complex factors that influence disease progression, healthcare professionals can develop more effective strategies to combat multiple myeloma and improve the lives of patients.

AI Search Multiple angles on this topic

Integrating New Evidence into Practice

The landscape of multiple myeloma treatment continues to evolve rapidly, with new evidence emerging from major oncology conferences. Clinicians face the challenge of integrating new research findings into existing treatment paradigms while considering individual patient needs. The heterogeneity of multiple myeloma requires a multifaceted approach to treatment selection and monitoring. Ongoing collaboration between researchers and clinicians is essential to translate scientific advances into improved patient outcomes.

Hope on the Horizon

Multiple myeloma is a hematological malignancy that poses significant treatment challenges due to its heterogeneity and propensity for relapse. In the last two decades, the therapeutic landscape has changed dramatically, but the disease remains largely incurable. New therapies and innovative delivery methods are transforming outcomes and quality of life for patients with early relapsed multiple myeloma. Breakthroughs presented at recent ASCO and EHA meetings offer hope for improved survival and quality of life.

Systemic Considerations

The management of multiple myeloma requires coordination across multiple healthcare disciplines and settings. Access to advanced therapies and clinical trials varies significantly by geographic location and healthcare system. The financial burden of novel treatments poses challenges for patients and healthcare systems alike. Addressing these systemic issues is crucial to ensuring equitable access to the latest treatment advances.

Living with Myeloma

Beyond the clinical data, the impact of multiple myeloma extends to patients' daily lives and well-being. The uncertainty of living with a relapsing disease creates significant emotional and psychological challenges. Patients and their families navigate complex treatment decisions while managing the physical effects of both the disease and its treatment. Support systems and patient education play crucial roles in helping individuals cope with the challenges of living with multiple myeloma.

What early relapse means for survival

  • 31 monthsAmong patients who relapsed after auto-SCT, median survival from relapse was 10.8 months for early relapse, compared with 41.8 months for later relapse—a difference of 31 months.[1]
  • 16.5 monthsFrom disease progression to death, median survival was 19.9 months in early relapse and 36.4 months in late relapse, a gap of 16.5 months.[2]

What the relapse comparisons add up to

Across these comparisons, early relapse marks a group with shorter survival than later relapse, whether survival is counted from relapse or from progression. These are group medians, not predictions for an individual patient.[1] [2]

Early progression is not confined to people with the risk markers examined: it was also observed in patients without them. That means the markers do not capture every route to an early relapse.[3]

What early-relapse prediction still needs to clarify

  • How can prediction methods account for early progression among patients who lack the risk markers already examined?[3]
  • Will the simplified score remain reliable across different datasets, given the conflicting results reported for it?[4]
  • How much could prediction change when biological information beyond FISH, or the omitted measurements in other analyses, is included?[5] [6]

Sources

  1. Impact of early relapse after auto-SCT for multiple myeloma. (pubmed.ncbi.nlm.nih.gov)
  2. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis. (pubmed.ncbi.nlm.nih.gov)
  3. Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma (pmc.ncbi.nlm.nih.gov)
  4. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling (pmc.ncbi.nlm.nih.gov)
  5. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk (pmc.ncbi.nlm.nih.gov)
  6. Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is the Revised International Staging System (R-ISS), and how does it relate to early relapse in multiple myeloma?

The Revised International Staging System (R-ISS) is a tool used to assess the risk of disease progression in multiple myeloma. It combines the International Staging System (ISS) with genetic markers and lactate dehydrogenase levels. The research indicates that patients with higher R-ISS stages (II and III) at diagnosis have a significantly increased risk of early relapse, which is defined as relapse within 24 months of Autologous Hematopoietic Cell Transplantation (AHCT). This suggests that the R-ISS is a key factor in predicting the likelihood of early relapse.

2

Besides the R-ISS, what other factors were identified as predictors of early relapse following Autologous Hematopoietic Cell Transplantation (AHCT)?

Besides the Revised International Staging System (R-ISS), the study identified a few other factors that increase the risk of early relapse after Autologous Hematopoietic Cell Transplantation (AHCT). These include a higher HCT-CI (Hematopoietic Cell Transplantation-Comorbidity Index) score, indicating the presence of comorbidities, and the use of multiple lines of induction chemotherapy prior to AHCT. These factors highlight the complex nature of multiple myeloma, where multiple aspects play a crucial role in prognosis.

3

How does the use of maintenance therapy impact the survival outcomes for multiple myeloma patients experiencing early relapse after Autologous Hematopoietic Cell Transplantation (AHCT)?

The research evaluated the impact of maintenance therapy on post-relapse survival. The study found that maintenance therapy did not significantly affect survival outcomes in the early relapse group. This suggests that for patients experiencing early relapse, the underlying biology of the disease plays a more significant role in determining outcomes than the use of maintenance therapy. This indicates the need for tailored treatments.

4

What is the significance of identifying predictors of early relapse in multiple myeloma, and how does this influence treatment strategies?

Identifying predictors of early relapse in multiple myeloma, like the Revised International Staging System (R-ISS) stage, HCT-CI score, and the number of induction chemotherapy lines, is crucial for improving patient outcomes. By understanding these factors, healthcare professionals can develop more personalized and targeted treatment strategies. This may involve adjusting the intensity of initial therapies, selecting alternative treatment approaches, or enrolling patients in clinical trials evaluating novel therapies. This helps in managing the disease more effectively and improving the lives of patients.

5

Can you explain the role of Autologous Hematopoietic Cell Transplantation (AHCT) in the context of multiple myeloma treatment, and why it's relevant to the study on early relapse?

Autologous Hematopoietic Cell Transplantation (AHCT) is a treatment approach for multiple myeloma where a patient's own blood-forming stem cells are collected and stored. Then, the patient receives high-dose chemotherapy to eliminate the cancer cells. After chemotherapy, the stored stem cells are infused back into the patient to help restore blood cell production. This study used AHCT as a point of reference, defining early relapse as relapse within 24 months of AHCT. The study's focus on early relapse within this timeframe underscores the importance of AHCT in the treatment pathway, as it helps to understand the factors that cause the disease to return shortly after this aggressive therapy.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.